Clinical Trials Logo

Skull Base Neoplasms clinical trials

View clinical trials related to Skull Base Neoplasms.

Filter by:

NCT ID: NCT06176989 Recruiting - Clinical trials for Metastatic Chondrosarcoma

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Start date: March 4, 2024
Phase: Phase 2
Study type: Interventional

Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body. These cancers may have mutations in a gene called IDH2. Researchers want to find out if a drug (enasidenib) that targets the IDH2 mutation can help people with these cancers. Objective: To test enasidenib in people with cancers of the nasal cavity or skull base. Eligibility: People aged 18 years and older with rare cancers of the nasal cavity or the base of the skull. Their cancer must have an IDH2 gene mutation, and it must have recurred locally or spread to other parts of the body. These cancers can include sinonasal undifferentiated carcinoma; olfactory neuroblastoma; sinonasal large-cell neuroendocrine carcinoma; poorly differentiated sinonasal adenocarcinoma; or chondrosarcoma. Design: Participants will be screened. They will have a physical exam with blood and urine tests and tests of their heart function. They will have imaging scans of their brain, skull base, neck, chest, abdomen, and pelvis. A sample of tumor tissue will be collected. Enasidenib is a tablet taken by mouth with a glass of water. Participants will take the drug once a day, every day, in 28-day cycles. They will not have resting periods between cycles. Participants will visit the clinic on the first day of each cycle to receive the tablets they will need to take at home until the beginning of the next cycle. They will keep a diary to record the time of each dose they take. Participants may remain in the study as long as the drug is helping them....

NCT ID: NCT05912881 Recruiting - Anosmia Clinical Trials

Chemosensory Dysfunction and Recovery in Endoscopic Endonasal Skull Base Surgery

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The investigators hypothesize that patients undergoing endoscopic endonasal skull base surgery experience clinically meaningful and modifiable disruptions in postoperative chemosensory function and quality of life, and the investigators further hypothesize that olfactory training in the postoperative period may significantly hasten normalization of patients' chemosensory perturbations. This tailored prospective study seeks to fulfill a significant gap in the understanding of the characteristics, implications, and treatment options for postoperative olfactory and gustatory impairment following endoscopic endonasal skull base surgery.

NCT ID: NCT05898074 Not yet recruiting - Clinical trials for Skull Base Neoplasms

Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.

NCT ID: NCT05733091 Recruiting - Tumors Clinical Trials

Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors

Start date: December 20, 2018
Phase:
Study type: Observational

To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer

NCT ID: NCT05607888 Recruiting - Clinical trials for Skull Base Neoplasms

Prospective Study of Sinonasal and Skull-base Tumours Management

Sinonasal_Tu
Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

This observational prospective clinical study aims to describe the epidemiology, management and outcome of patients with sinonasal and skull-base pathology (tumours and diseases with malignant clinical characteristics) in a tertiary otorhinolaryngology referral centre. The main questions it aims to answer are: - what is the caseload of patients with the included pathology in our centre - what are the results of management of these cases - what are the epidemiological characteristics of included patients - what is the quality of life of included patients.

NCT ID: NCT05101798 Recruiting - Neoplasm Clinical Trials

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

Start date: September 14, 2021
Phase: Phase 2
Study type: Interventional

This study allows head and neck cancer surgeons to specifically visualize cancerous cells apart from normal healthy tissue. 5-aminolevulinic acid (5-ALA) is a safe and effective FDA-approved agent successfully used by neurosurgeons for FGS of different brain tumors is given to the patients preoperatively. Using specific wavelengths of light as well as specialized magnified lenses the surgeons use this technique to assist in tumor resection.

NCT ID: NCT04374448 Not yet recruiting - Chronic Sinusitis Clinical Trials

Utility of Indocyanine Green Fluorescence in Endoscopic Sinonasal and Skull Base Surgery

NIRFICG
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The endoscope is a device placed into the nasal cavity to remove chronic sinus disease or tumor or create access into the skullbase for extensive tumor removal. Indocyanine Green (ICG) is a dye that is injected through an intravenous site and is used to light up vasculature and margins of a tumor during surgery. This helps avoid damage to important vasculature and obtain clear margins during surgery. This study aims to further assess the utility of ICG when operating within the nasal cavity or skullbase.

NCT ID: NCT04296617 Completed - Clinical trials for Malignant Central Nervous System Neoplasm

Brain Imaging Changes Following Proton Therapy for Pediatric Primary Central Nervous System and Base of Skull Tumors

Start date: January 21, 2019
Phase:
Study type: Observational

This trial gathers information from patients with primary central nervous system or base of skull tumors that receive proton beam therapy and see if certain imaging techniques can help detect radiation-related changes over time. This study may help providers learn more about proton beam radiotherapy and how to improve the way it is delivered.

NCT ID: NCT04265430 Recruiting - Osteoradionecrosis Clinical Trials

Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors

Start date: September 17, 2018
Phase: Phase 4
Study type: Interventional

This phase IV trial studies how well serial magnetic resonance imaging (MRI) after radiation therapy works in predicting radiation-induced changes in the normal tissue of patients with oral cavity or skull base tumors. Performing MRIs after radiation therapy for patients with oral cavity or skull base tumors may help to predict osteoradionecrosis (a change in non-cancerous tissue).

NCT ID: NCT04249921 Recruiting - Quality of Life Clinical Trials

Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base

Start date: November 20, 2019
Phase:
Study type: Observational

Skull base tumors are a type of tumor that grow in the area of several skulls behind the cranial cavity. The incidence rate is 2 to 18 per 100,000 people per year; males and females are likely to have a proportional difference in the types of skull base tumors. Cerebellopontine angle (CPA) tumors are the most common neoplasms in the posterior skull base,accounting for 5-10% of skull base tumors.Some different kinds of tumors can grow in cerebellopontine angle. The tumors are more likely to cause some symptoms when they grow large enough to put pressure on the brain. A common traditional treatment for skull base tumors is neurosurgery-craniotomy. However, after the operation, brain may be injured with hematoma, and the instruments used are in contact with the brain. It is still inevitable that there will have complications of minor and major nerve damages, such as facial paralysis,trigeminal neuralgia, tinnitus, sports disorders (ataxia) and so on. Acupuncture has a unique effect on the treatment of the human nervous system. Aim of the study is used acupuncture to improve the complications of the surgery of Cerebellopontine angle tumors in skull base.